fore, we decided to look for selectivity among the effects cyclase (sGC)-mediated vascular smooth muscle rerather than the production of NO. One of the main nilaxation. We demonstrate here that, while NO synthase trosation targets of NO is the heme-iron present in (NOS) inhibitors exacerbated toxicity, inhibitors of sGC soluble guanylate cyclase (sGC), thereby activating the activation protected against TNF-induced lethality, enzyme resulting in cGMP accumulation and cGMPbradycardia, and hypotension. Importantly, sGC inhidependent cardiovascular changes such as vascular rebition did not interfere with the antitumor activity of laxation, myocardial depression, and the inhibition of TNF. Using NOS inhibitors or iNOS-deficient animals, platelet aggregation and adhesion (Waldman and Murad, we furthermore observed that no protection against 1987; Wolkow, 1998). TNF toxicity could be obtained in the absence of NO. 
Figure 1. Lethality Induced by TNF in the Four Models
The total number of mice used is indicated above each bar. All mice were i.v. challenged with a 100% lethal dose of mTNF or hTNF, determined with the same lot of TNF and mice before the start of each individual experiment. Open bars represent control mice pretreated with glucose (six mice for each model) or PBS (the numbers indicated above the open bar minus six). Cross-hatched bars are mice that received 100 mg/kg L-NMMA, L-NAME, or L-NIO either 2 hr or 30 min before, together, or 5, 30, or 90 min after TNF. Independent of the NOS inhibitor used or the time point of its administration, mice could never be protected. Closed bars represent mice pretreated with MB at the time indicated below the bars. Lethality was scored up to 7 days after TNF challenge. Generally, various treatment groups were compared in one single experiment using five to seven mice per group. The results shown for models I, II, and III represent the combination of up to five independent experiments. Data for model IV come from one single experiment. eNOS-) deficient mice could never be significantly proactivation, mice were protected very efficiently against TNF-induced mortality in all four models (Figure 1 ). tected. We therefore conclude a bivalent role for NO in TNF-induced toxicity: on the one hand mediating bradyGiven the significant protection by MB, we next determined whether another inhibitor of sGC activation, cardia, hypotension, and subsequent shock via sGC activation; on the other hand exerting a protective and LY83583 (Malta et al., 1988) , had a similar effect against mTNF-induced mortality. As plotted in Figure 2 , LY83583 cGMP-independent function, essential to survive. Contrary to the general assumption, the source for this proproved as capable as MB to protect. To further substantiate the involvement of sGC-induced cGMP accumulatective NO is iNOS and not eNOS, prompting us to question the feasibility of selective iNOS inhibition as a tion in TNF lethality, MB pretreatment was combined with multiple injections of zaprinast, a specific inhibitor strategy to provide protection against TNF-induced or -mediated diseases.
of type V cGMP phosphodiesterase increasing cGMP concentrations (data not shown). Zaprinast was injected i.v. four times (together with, as well as 2, 5, and 8 hr Results after mTNF), a treatment not lethal as such but very efficient to abrogate MB protection (data not shown).
MB and LY83583, but Not NOS Inhibitors, Protect against TNF-Induced Lethality
Effect of MB on TNF-Induced cGMP Production, To investigate the role of NO and sGC in TNF-induced Bradycardia, and Hypotension shock, we performed experiments in four different leThe experiments using MB, LY83583, and zaprinast indithality models in mice. In model I, nonsensitized mice cated that sGC is a pivotal detrimental mediator of TNFare i.v. challenged with a 100% lethal dose of mouse induced lethality. To assure that MB is actually blocking (m) TNF, typically ranging from 20 to 30 g. In the other three models, human (h) TNF, which is normally not lethal in healthy mice except at extremely high doses (LD 50 Ϸ 500 g), is injected in sensitized mice. Mice are sensitized by the presence of an i.m. LLC tumor (model II), a BCG infection (model III), or repeated IL-12 injections (model IV). Sensitization models were described in detail before (Cauwels et al., 1995 (Cauwels et al., , 1996 . Essentially, model III and IV may be regarded molecularly equivalent since BCG sensitization can be abrogated by anti-IL-12 treatment and both models were shown to depend on endogenous IFN␥ for sensitization (Cauwels et al., 1995 (Cauwels et al., , 1996 .
Treatment of mice with different NOS inhibitors (L-NAME, L-NMMA, or L-NIO) at various time points (before, together, or after TNF challenge) could not protect Figure 4B ). MAP data after TNF challenge showed an immediate transient drop in blood pressure, followed by the delayed hypotension. Nonlethal TNF doses caused minor hypotension (data not shown), whereas a lethal TNF injection resulted in severe hypotension (Ͼ40 mmHg MAP reduction) within the 10 hr observation period in 4/7 animals ( Figure 4C ). When mice were pretreated with MB, this severe hypotension was never observed ( Figure 4D ). All mice pretreated with Evidence for a Protective Role of NO in TNF-Induced Shock sGC activation, cGMP was measured in plasma and kidney homogenates. Mice showed increased cGMP To determine why sGC but not NOS inhibition can protect mice from a lethal TNF challenge (Figure 1 ), MB concentrations peaking about 5 hr after mTNF injection, and this increase was downmodulated by MB pretreatand L-NAME treatments were combined. MB protection was totally abrogated by L-NAME in models I and II, ment (Figure 3 ).
In the cardiovascular system, NO-induced cGMP acwhere the L-NAME injection was capable of reducing serum NO levels to below basal values ( Figure 5 ). In cumulation in shock accounts for the relaxation of vascular smooth muscle cells and myocytes, causing vasomodels III and IV, however, L-NAME could not completely eliminate the systemic presence of NO (not even dilatation and myocardial depression, respectively. To evaluate the effect of MB on TNF-induced hemodynamic when L-NAME was injected twice at a 5-fold higher dose; data not shown) and MB could still provide 100% changes, mean arterial blood pressure (MAP) and heart rate (HR) were monitored continuously in free-moving protection even in combination with L-NAME treatment ( Figure 5 ). It should be noted that in these latter models conscious mice. Both HR and MAP dropped drastically within 5 min of MB pretreatment, but recovered fast and the mere presence of a BCG infection or IL-12 sensitization caused a substantial presence of NO x Ϫ in circulation were back to seminormal levels at the time of mTNF injection 2 hr later ( Figures 4B and 4D ). TNF lethality before TNF was administered ( Figure 5 , open bars). Taken together, these data imply that MB can no longer could invariably be predicted by a severe drop in HR starting only a couple of hours after the TNF challenge protect against TNF-induced lethality if NO is completely Figure 6C ) and not at all in tumor and 100% survival of the tumor-free mice (data model III ( Figure 6D ). In addition, treatment with LY83583 not shown). Hence, we conclude that MB pretreatment could not protect iNOS-deficient mice against TNF morimpairs toxicity but not the antitumor potential of TNF, tality (data not shown). These results clearly prove that allowing a complete cure of tumor-bearing mice. in the absence of iNOS MB or LY83583 fails to protect against TNF lethality, implicating iNOS as the source of protective NO in TNF toxicity. Discussion
MB pretreatment in model I (

MB Prevents Systemic Toxicity but Not the Antitumor
In addition to the detrimental role of NO in shock-like Activity of TNF diseases, described in a plethora of reports during the TNF is a very potent antitumor agent, but its systemic last decade, studies in animal models and clinical trials use is seriously limited due to its shock-inducing properusing NOS inhibitors suggest a beneficial role for NO as ties. We have identified MB as a drug to prevent TNFwell. The disappointing results obtained with nonselecinduced systemic toxicity and lethality. However, to be tive NOS inhibitors resulted in a quest for selective iNOS considered therapeutically valuable, we needed to verify inhibitors, based upon the involvement of eNOS in the whether MB interferes with the antitumor activity of TNF normal regulation of vascular tone and the upregulation or not. For this purpose, we tested the effect of MB of iNOS in inflammatory conditions. Still, discrepant repretreatment on the antitumor efficacy of mTNF and sults have been obtained using these iNOS-selective mIFN␥ against a syngeneic murine B16BL6 melanoma inhibitors in various endotoxic shock models. For that tumor. As described previously (Brouckaert et al., 1986) , reason, we started to question the advantage of selecdaily treatment of tumor-bearing mice with a combinative iNOS inhibitors as therapeutic agents and decided tion of 10 g mTNF and 5000 IU mIFN␥ caused a comto aim for the selective inhibition of NO-mediated effects plete regression of the tumor ( Figure 7A ) but proved rather than NO production. So far, sGC is the only contoxic resulting in 100% lethality by the end of the treatclusively proven receptor for NO and is involved in many ment ( Figure 7B Hence, we conclude that in nonanesthetized mice a lethal TNF challenge is predictably accompanied by seThis indicates again that MB does not simply protect via a superoxide-mediated mechanism. Furthermore, we vere bradycardia and, in about half the cases, by profound hypotension within 10 hr after injection. Both caractually demonstrated that MB prevents TNF-induced cGMP production in vivo (Figure 3) and that zaprinast, a diovascular changes are without exception efficiently prevented by a life-saving MB treatment. cGMP phospodiesterase inhibitor that increases cGMP accumulation, abolished MB protection (data not shown).
In an attempt to understand why inhibition of sGC activation but not NO blockade could protect mice Taken together, these observations convincingly argue for inhibition of the activation of sGC to be the mechaagainst TNF lethality, we combined MB treatment with L-NAME injection and found evidence for an indispensnism of protection by MB against TNF-induced mortality. Further evidence may come from studies using able protective role for NO in TNF toxicity, in addition to its sGC-mediated detrimental activities. Using eNOSknockout mice, which are currently being constructed.
When evaluating the effect of MB on TNF-induced and iNOS-deficient mice, we could confirm this protective effect. Whereas eNOS-deficient animals behaved cardiovascular changes, we found that it very efficiently alleviated both bradycardia and hypotension. In septic just like wild-type mice, iNOS-deficient mice could not be protected: not by MB ( Figure 6C and 6D , 1996) , and the activation of cyclooxygenase (Salvemini et al., 1996) . NO was (Figure 4B ), an effect we also observed in case of a nonlethal TNF injection (data not shown). also shown to interfere with apoptosis via mechanisms other than S-nitrosylation-mediated caspase inhibition, Excessive vasodilatation and vascular hyporeactivity with ensuing refractory hypotension have long been but the cGMP dependency of most of these effects remains controversial (Dimmeler and Zeiher, 1997). considered hallmarks of septic shock. In endotoxic animal models, it was proven that delayed hypotension in Taken together, our results indicate that in conscious mice TNF exerts its lethal effects via sGC activation, shock is mediated by NO exerting its vasorelaxatory properties mainly via the activation of sGC. Also in a invariably accompanied by severe bradycardia and in about half the cases by profound hypotension within 10 hTNF-induced shock model in anesthetized dogs, NOdependent hypotension was shown to develop following hr of observation. Pretreatment with MB can efficiently prevent TNF-induced cGMP accumulation, bradycardia, sublethal TNF injection (Kilbourn et al., 1990) . In most phase I clinical TNF trials, hypotension reliably occurred hypotension, and mortality but does not interfere with antitumor activities, thus broadening the therapeutic poand a severe drop of systolic blood pressure (Ͼ40 mmHg) was observed in 25% of the evaluable patients tential of systemic TNF as an anticancer treatment. In 
